TIE2 (Y897H)
Sign in to save this workspaceTEK · Variant type: point · HGVS: p.R915C
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ripretinib | 91.6% | 8.4% | 92.95 |
| 2 | Repotrectinib | 91.5% | 8.5% | 84.21 |
| 3 | Tivozanib | 87.9% | 12.1% | 92.42 |
| 4 | Erdafitinib | 74.0% | 26.1% | 95.71 |
| 5 | Infigratinib | 68.5% | 31.5% | 98.24 |
| 6 | Pemigatinib | 66.3% | 33.7% | 98.23 |
| 7 | Selpercatinib | 65.4% | 34.6% | 96.72 |
| 8 | Neratinib | 61.9% | 38.1% | 93.18 |
| 9 | Vandetanib | 58.3% | 41.7% | 95.74 |
| 10 | Entrectinib | 47.3% | 52.7% | 93.69 |
| 11 | Defactinib | 43.3% | 56.7% | 92.68 |
| 12 | Pacritinib | 42.3% | 57.7% | 88.64 |
| 13 | Apatinib | 41.7% | 58.3% | 97.73 |
| 14 | Sorafenib | 39.2% | 60.8% | 96.72 |
| 15 | Umbralisib | 37.3% | 62.7% | 98.74 |
| 16 | Canertinib | 34.1% | 65.9% | 96.49 |
| 17 | Fedratinib | 32.3% | 67.7% | 96.21 |
| 18 | Upadacitinib | 25.1% | 74.9% | 97.98 |
| 19 | Futibatinib | 22.0% | 78.0% | 98.48 |
| 20 | Erlotinib | 20.4% | 79.6% | 99.75 |
| 21 | Gilteritinib | 18.3% | 81.7% | 88.97 |
| 22 | Pralsetinib | 15.8% | 84.2% | 93.43 |
| 23 | Sunitinib | 14.8% | 85.2% | 91.73 |
| 24 | Paxalisib | 13.8% | 86.2% | 99.75 |
| 25 | Avapritinib | 13.7% | 86.3% | 97.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ripretinib | 91.6% | — | — |
| Repotrectinib | 91.5% | — | — |
| Tivozanib | 87.9% | — | — |
| Erdafitinib | 74.0% | — | — |
| Infigratinib | 68.5% | — | — |
| Pemigatinib | 66.3% | — | — |
| Selpercatinib | 65.4% | — | — |
| Neratinib | 61.9% | — | — |
| Vandetanib | 58.3% | — | — |
| Entrectinib | 47.3% | — | — |
| Defactinib | 43.3% | — | — |
| Pacritinib | 42.3% | — | — |
| Apatinib | 41.7% | — | — |
| Sorafenib | 39.2% | — | — |
| Umbralisib | 37.3% | — | — |
| Canertinib | 34.1% | — | — |
| Fedratinib | 32.3% | — | — |
| Upadacitinib | 25.1% | — | — |
| Futibatinib | 22.0% | — | — |
| Erlotinib | 20.4% | — | — |
| Gilteritinib | 18.3% | — | — |
| Pralsetinib | 15.8% | — | — |
| Sunitinib | 14.8% | — | — |
| Paxalisib | 13.8% | — | — |
| Avapritinib | 13.7% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.7ms